$SLRX
Salarius Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000161521923000071 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $910.8K $1.500M
YoY Change -49.18% -18.12%
% of Gross Profit
Research & Development $59.95K $1.036M
YoY Change -98.72% -72.66%
% of Gross Profit
Depreciation & Amortization $50.00 $10.00K
YoY Change -97.01% 498.8%
% of Gross Profit
Operating Expenses $970.7K $2.532M
YoY Change -85.02% -82.52%
Operating Profit -$2.532M
YoY Change -82.52%
Interest Expense $88.91K $89.37K
YoY Change -16.86% 14.18%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$881.8K -$2.440M
YoY Change -86.16% -83.07%
Income Tax
% Of Pretax Income
Net Earnings -$881.8K -$2.443M
YoY Change -86.16% -83.05%
Net Earnings / Revenue
Basic Earnings Per Share -$0.65
Diluted Earnings Per Share -$0.22 -$0.65
COMMON SHARES
Basic Shares Outstanding 3.938M shares 3.641M shares
Diluted Shares Outstanding 3.754M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.900M $7.600M
YoY Change -51.27% -54.82%
Cash & Equivalents $5.900M $7.581M
Short-Term Investments
Other Short-Term Assets $151.3K $83.12K
YoY Change -9.73% -66.57%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $6.520M $8.324M
YoY Change -55.1% -53.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $66.85K $80.44K
YoY Change -48.77% -45.07%
Total Long-Term Assets $66.85K $80.44K
YoY Change -48.77% -95.42%
TOTAL ASSETS
Total Short-Term Assets $6.520M $8.324M
Total Long-Term Assets $66.85K $80.44K
Total Assets $6.587M $8.404M
YoY Change -55.04% -57.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $602.9K $1.089M
YoY Change -78.91% -36.58%
Accrued Expenses $406.8K $800.0K
YoY Change -71.11% -42.61%
Deferred Revenue
YoY Change
Short-Term Debt $289.6K $500.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.299M $2.300M
YoY Change -69.55% -26.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.299M $2.300M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.299M $2.321M
YoY Change -69.55% -25.4%
SHAREHOLDERS EQUITY
Retained Earnings -$76.35M -$75.47M
YoY Change 19.66% 31.4%
Common Stock $393.00 $394.00
YoY Change 74.67% 75.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.287M $6.084M
YoY Change
Total Liabilities & Shareholders Equity $6.587M $8.404M
YoY Change -55.04% -57.39%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$881.8K -$2.443M
YoY Change -86.16% -83.05%
Depreciation, Depletion And Amortization $50.00 $10.00K
YoY Change -97.01% 498.8%
Cash From Operating Activities -$1.516M -$3.740M
YoY Change -67.84% -34.86%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -170.4K -210.0K
YoY Change 145.07%
NET CHANGE
Cash From Operating Activities -1.516M -3.740M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -170.4K -210.0K
Net Change In Cash -1.687M -3.950M
YoY Change -64.22% -32.21%
FREE CASH FLOW
Cash From Operating Activities -$1.516M -$3.740M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2442816 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14409457 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.84
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3754028 shares
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0 usd
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1610490 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
743196 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
803373 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8323784 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14520298 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
80444 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
130501 usd
CY2023Q3 us-gaap Assets
Assets
8404228 usd
CY2022Q4 us-gaap Assets
Assets
14650799 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1088640 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2858330 usd
CY2023Q3 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
772794 usd
CY2022Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1407861 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
313903 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5015 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y6M
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
459091 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2320525 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4266191 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2255899 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2255899 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
394 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
225 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
81549354 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
74189531 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75466045 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63805148 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6083703 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10384608 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8404228 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14650799 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7113794 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11151170 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4810449 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5346181 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8865909 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8865909 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2532185 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
14488064 usd
us-gaap Operating Expenses
OperatingExpenses
11924243 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2532185 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25363260 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
89369 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
126240 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2442816 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-14409457 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11660897 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-25237020 usd
us-gaap Net Income Loss
NetIncomeLoss
-11660897 usd
us-gaap Net Income Loss
NetIncomeLoss
-25237020 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.41
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.13
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3754028 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2247753 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2247753 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3037547 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3037547 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2081023 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2081023 shares
us-gaap Net Income Loss
NetIncomeLoss
-11660897 usd
us-gaap Net Income Loss
NetIncomeLoss
-25237020 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8946 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5008 usd
us-gaap Share Based Compensation
ShareBasedCompensation
439462 usd
us-gaap Share Based Compensation
ShareBasedCompensation
651296 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8865909 usd
flks In Process Research And Development Technology
InProcessResearchAndDevelopmentTechnology
0 usd
flks In Process Research And Development Technology
InProcessResearchAndDevelopmentTechnology
1987900 usd
flks Grant Receivable Write Off
GrantReceivableWriteOff
130000 usd
flks Grant Receivable Write Off
GrantReceivableWriteOff
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1480490 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-671848 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
154192 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1769690 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
173486 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-635067 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
826078 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11334908 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12881535 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1500000 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
6920530 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1987375 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
111469 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6809061 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1987375 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4525847 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12394160 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12106435 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29214380 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7580588 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16820220 usd
us-gaap Interest Paid Net
InterestPaidNet
6799 usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
487900 usd
flks Insurance Premium Financed By Note Payable
InsurancePremiumFinancedByNotePayable
570560 usd
flks Insurance Premium Financed By Note Payable
InsurancePremiumFinancedByNotePayable
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38722985 usd
CY2022Q1 flks Stock Issued During Period For In Process Research And Development Technology Value New Issues
StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues
487900 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4718338 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30884129 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
134316 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3548 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14409457 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16612536 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10384608 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
311681 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
203345 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5340773 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5558861 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6608790 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
123459 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3877308 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8413802 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
112658 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2442816 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6083703 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8900000 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8900000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. </span></div>Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10964113 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
706400 shares
CY2022Q1 flks Payments For Acquisition And Strategic Collaboration Agreement
PaymentsForAcquisitionAndStrategicCollaborationAgreement
2000000 usd
CY2022Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1500000 usd
CY2023Q3 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1500000 usd
flks Proceeds From Grants Received
ProceedsFromGrantsReceived
16000000 usd
CY2023Q3 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
0 usd
CY2022Q4 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
11185 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
660077 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624612 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
83119 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
167576 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
743196 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
803373 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
500000 usd
CY2020Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
29.55
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y6M
CY2022Q2 flks Warrants And Rights Exercisable Term
WarrantsAndRightsExercisableTerm
P6M
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
590087 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
51360 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
500000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0162
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0170
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.2519
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.2642
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
63919 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
68.75
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
51360 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1375 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
108889 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M10D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
36301 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
35.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M17D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
107128 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.67
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M14D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
107128 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M14D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
71142 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M9D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1000000 usd

Files In Submission

Name View Source Status
flks-20230930_pre.xml Edgar Link unprocessable
0001615219-23-000071-index-headers.html Edgar Link pending
0001615219-23-000071-index.html Edgar Link pending
0001615219-23-000071.txt Edgar Link pending
0001615219-23-000071-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
flks-20230930.htm Edgar Link pending
flks-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrx20230930ex-311.htm Edgar Link pending
slrx20230930ex-312.htm Edgar Link pending
slrx20230930ex-321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
flks-20230930_cal.xml Edgar Link unprocessable
flks-20230930_def.xml Edgar Link unprocessable
flks-20230930_lab.xml Edgar Link unprocessable
flks-20230930_htm.xml Edgar Link completed